Base specific interaction of reductively activated nitroimidazoles with DNA  by Declerck, P.J. et al.
Volume 164, number 1 FEBS 1014 November 1983 
Base specific interaction of reductively activated 
nitroimidazoles with DNA 
P.J. Declerck, C.J. De Ranter and G. Volckaert* 
Instituut voor Farmaceutische Wetenschappen, Laboratorium voor Analytische Chemie en Medicinale Fysicochemie, 
Katholieke Universiteit Leuven, Van Evenstraat 4 and *Faculteit Geneeskunde, Rega Instituut, 
Katholieke Universiteit Leuven, Minderbroedersstraat IO, B-3000 Leuven, Belgium 
Received 9 September 1983 
To exert biological activity, nitroimidazole drugs require reductive activation in vivo. Nucleic acids are 
susceptible to the activated drug in vitro and are presumably the major target in vivo. We carried out 
electrolytical reduction of several S-nitroimidazoles at a controlled potential either in the presence or prior 
to the addition of DNA. Using a nucleotide sequence specific test to analyse cleavage products, specific 
interaction of the reduced nitroimidazole intermediate(s) towards the guanine residues is prominent. Since 
the strand scission depends on subsequent piperidine treatment, it can be concluded that the primary 
interaction between the activated drug and guanine is a covalent modification weakening the glycosidic 
bond. 
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1. INTRODUCTION 
Nitroimidazole drugs are extensively used against 
infections caused by anaerobic bacteria and pro- 
tozoa [1,2]. They also received much attention 
in cancer therapy as radiosensitizers of hypoxic 
tumours and by their direct cytotoxic effects to- 
wards hypoxic cells [3]. The precise mechanism of 
action of these drugs is unknown, as well as their 
site(s) of interaction with cellular macromolecules. 
Most probably, nucleic acids are a major target 
t41. 
ducts were analysed by comparison with the appro- 
priate chemical degradation sequencing ladders to 
assess the susceptibility of the DNA to the drug 
and its nucleotide and/or sequence specificity 
[9,W. 
2. MATERIALS AND METHODS 
2.1. Envmes, DNA and chemicals 
Reduction of the nitro group is an essential step 
in the activation of nitroimidazoles. The resulting 
reactive intermediates are elusive, but in vitro 
generation of these intermediates in the presence of 
DNA has clearly shown a direct interaction of the 
activated nitromidazoles with DNA [5-S]. These 
experiments, however, did not reveal unambigu- 
ously the nature of the target site in the DNA. In 
an attempt to unravel this interaction, we used 
end-labelled DNA fragments as substrates for 
several activated nitroimidazoles. Reaction pro- 
HinfI and NaeIII were purchased from New 
England Biolabs (Beverly, USA) and used as recom- 
mended. DNA polymerase I (Klenow) was from 
Boehringer (Mannheim). pGVOO1 is a deletion deri- 
vative of pBR327 [Volckaert et al., in preparation]. 
All chemicals were of analytical grade. Ornidazole 
[1-(3-chloro-2-hydroxypropyl)-2-methyl-5-nitroimi- 
dazole], dimetridazole (1,2-dimethyl-5-nitroimida- 
zole), ronidazole [l-methyl-Z[(carbamoyloxy)-me- 
thyl]-5nitroimidazolel and MK-910 [2-(4-fluoro- 
phenyl)-1-methyl-5-nitroimidazole], carnidazole 
[O-methyl-(2-(2-methyl-5-nitroimidazol-l-yl)ethyl]- 
thiocarbamate], nimorazole [l-(2-N-morpholinyl- 
ethyl)-5-nitroimidazole] were gifts from Roche 
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(Belgium), May and Baker (Essex), Merck Sharp 
and Dohme (NJ), Janssen Pharmaceutics (Belgium) 
and Carlo Erba (Italy), respectively. 
2.2. Preparation of the end-labelled DNA 
fragments 
DNA fragments were prepared by double diges- 
tion of pGVOO1 DNA (Volckaert et al., in prepara- 
tion) with the restriction enzymes HaeIII and 
HinfI. The sample was treated with phenol and the 
DNA was precipitated with ethanol. Subsequently 
the fragments were radiolabelled by elongation of 
the 3’ recessed HinfI-ends with DNA polymerase 
I (Klenow fragment A) in the presence of dGTP 
and ]cu-32P]dATP [l 11. Those fragments generated 
by one HaeIII and one HinfI cleavage are single- 
end labelled by this procedure. 
The labelled digest was fractionated by electro- 
phoresis on a 5% polyacrylamide gel in 0.04 M 
Tris-0.02 M sodium acetate (pH 7.8). The labelled 
fragments were located by autoradiography, ex- 
cised and duted by gently shaking in 1 M NaCI at 
room temperature for at least 1 h. The supernatant 
was filtered on Sephadex G-50, mixed with an 
equal volume of isopropanol and chilled at -20°C 
for 30min to precipitate the DNA. The DNA was 
subsequently pelleted, washed with ethanol, dried, 
redissolved in water and stored at -20°C. Frag- 
ments labelled at one end only were selected for 
further experiments. 
2.3. Electrolytic reduction 
Controlled potential electrolysis was perfor- 
med using a 3 electrode configuration (Tacussel 
G~n~rateur Coulom~trique type GCU) involving a 
mercury pool as working electrode (cathode), a 
platinum wire counter electrode and a saturated 
calomel reference electode (SCE). Reoxidation of 
the generated reduction products was prevented by 
separating the counter electrode from the working 
solution with a sintered glass disc. 
The cathodic compartment contained I ml of a 
solution of nitroimidazole in 15 mM NaCl, 1.5 mM 
sodium citrate (pH 7.0). To this solution 100~1 
end-labelled DNA was added. The anodic com- 
partment contained 15 mM NaCl and 1.5 mM 
sodium citrate (pH 7.0). Since oxygen prevents 
nitro-reduction 111 the solution was purged with Nz 
to remove all traces of oxygen. 
The reductive activation of the nitroimidazoles 
146 
was carried out at a constant potential of -900 mV 
vs SCE. Control samples with DNA fragment in 
the absence of nitroimidazoles were included in all 
experiments to ascertain the absence of DNA de- 
gradation by electrolysis [ 12,131. 
2.4. Analysis of the DNA 
After electrolytic reduction the content of the 
reaction vessel was dispensed into two Eppendorf 
tubes (500~1 each). 50~1 of 3 M sodium acetate 
and 550~1 isopropanol were added and chilled at 
-20°C for 1 h. Subsequently, the DNA was pel- 
leted, washed with 80% ethanol and redissolved in 
150111 of 0.3 M NaOAc (pH 7.2). The DNA was re- 
precipitated with 2.5~01s ethanol at -70°C for 
15 min. One of the samples was treated with piperi- 
dine and evaporated to dryness as described for 
chemical DNA sequencing [14,151. In parallel, a 
set of base-specific hemical degradation reactions 
was carried out as in [ 14,151. All prepared samples 
were loaded in adjacent slots on a thin 8% se- 
quencing gel [ 161. 
After electrophoresis the DNA was fixed by im- 
mersing the gel for 15 min in a solution of 10% 
acetic acid. The gel was subsequently dried and ex- 
posed at ambient temperature to a Kodak X-omat 
AR film. 
3. RESULTS AND DISCUSSION 
In order to reveal the specificity of reaction of 
reduced nitroimidazoles with DNA, we treated 
single-end-labelled DNA fragments with the drug 
and ran the reaction products in adjacent lanes on 
sequencing gels. This approach has previously 
been used successfully to demonstrate the inter- 
action of the antitumour antibiotics bleomycin and 
neocarzinostatin with DNA [9,10]. We performed 
experiments with different nitroimidazoles. Reduc- 
tion of the nitro group is a prerequisite for the bio- 
logical activity of the drug. Accordingly, we did 
not detect any degradation by exposing of the 
DNA to the parent drug. After treatment with re- 
ductively activated drug the DNA backbone is still 
largely intact, although sometimes light degrada- 
tion is found (fig. 1, lanes, 2a,3a). Extensive degra- 
dation, however, can be induced by piperidine, 
which displaces modified bases from the DNA and 
cleaves the chain at positions rendered vulnerable 
by modification (fig.1, lanes 2b,3b). Since the 
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Fig. 1. Determination of the base specificity of the inter- 
action of reductively activated orfiidazole with DNA. 
(A) Reductive activation in the presence of DNA; 
(B) addition of the DNA after electrolytic reduction of 
ornidazole. (1) 1 x 10e2 M NaNO2, (2) 5 x 1O-3 M orni- 
dazole, (3) 5 x 10s4 M ornidazole, (4) 5 x 10m2 M ornida- 
zole. Each sample is run before (a) and after (b) piperi- 
dine treatment. Sequencing degradations (G, AG, AC, 
TC, C, P) are shown below a heavy bar (P is a control 
sample treated with piperidine only). The top of the 
figure does not represent the position of the gel slots. 
slight degradation bbserved in the absence of 
piperidine treatment is at identical positions to 
those induced by piperidine, we assume that the 
former scissions occur during the manipulation 
steps prior to gel electrophoresis (e.g. during boiling 
of the samples before loading the gel). Exposure of 
the DNA fragment to electrolysis in the presence of 
NaNOt, but in the absence of the drug, does not 
lead to degradation (fig. 1, lanes 1 a, 1 b). This shows 
that the reactive intermediate is not the nitrite ion. 
Addition of the DNA to the activated drug, i.e. 
after electrolytic reduction, yields an identical de- 
gradation pattern (fig.1, lanes 4a,4b). This indi- 
cates that the reactive intermediate is relatively 
stable in the absence of DNA. 
Fig. 1 clearly shows that degradation of the DNA 
fragment occurs almost exclusively at guanine resi- 
dues. There is no sequence specificity. Minor 
cleavages occur at some, but not all, T residues. It 
should be stressed that only modifications can be 
observed which are prone to displacement by 
piperidine. The nature of the G modification re- 
mains to be determined, as well as the in vivo 
mechanism(s) by which this modification may be 
responsible for the mutagenic and radiosensitizing 
activities of the drug. The cleavage pattern shown 
in fig. 1 after treatment with ornidazole is identical 
with those obtained with other nitroimidazoles, 
e.g. dimetridazole, ronidazole, MK-910, carnida- 
zole and nimorazole (not shown). 
All investigations previously described were 
based mainly upon changes of the physicochemical 
properties of the DNA or of DNA-containing solu- 
tions, such as viscometry, spectrophotometry, 
determination of melting temperature and re- 
naturation profiles, determination of the single 
strand breaks by standard methods such as sucrose 
gradient ultracentrifugation. In contrast to our 
results, these experiments revealed fragmentation 
of DNA by activated nitroimidazoles [6-81. Such 
fragmentation, however, might be restricted to the 
use of macromolecular DNA by these authors. We 
cannot exclude sequence specificity in this case. In 
addition, a preferential release of thymidine phos- 
phates after electrolytic reduction of misonidazole 
[ I-(3-methoxy-2-hydroxypropyl)-2-nitroimidazole] 
in the presence of DNA was observed in [8]. 
Our results are in agreement with the findings of 
authors in [Sj who showed that the interaction of 
chemically reduced nitroimidazoles with DNA is 
directly proportional to the G + C content. This 
was also confirmed recently by authors in [ 171 who 
described the modification of guanine by chemi- 
cally reduced 2-nitroimidazoles. 
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